share_log

Allarity Therapeutics Analyst Ratings

Benzinga Analyst Ratings ·  Aug 23, 2022 07:10
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
08/23/2022 Ladenburg Thalmann Downgrades Buy → Neutral
05/27/2022 426.32% Ladenburg Thalmann → $8 Initiates Coverage On → Buy

Allarity Therapeutics Questions & Answers

What is the target price for Allarity Therapeutics (ALLR)?

The latest price target for Allarity Therapeutics (NASDAQ: ALLR) was reported by Ladenburg Thalmann on August 23, 2022. The analyst firm set a price target for $0.00 expecting ALLR to fall to within 12 months (a possible -100.00% downside). 2 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Allarity Therapeutics (ALLR)?

The latest analyst rating for Allarity Therapeutics (NASDAQ: ALLR) was provided by Ladenburg Thalmann, and Allarity Therapeutics downgraded their neutral rating.

When is the next analyst rating going to be posted or updated for Allarity Therapeutics (ALLR)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Allarity Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Allarity Therapeutics was filed on August 23, 2022 so you should expect the next rating to be made available sometime around August 23, 2023.

Is the Analyst Rating Allarity Therapeutics (ALLR) correct?

While ratings are subjective and will change, the latest Allarity Therapeutics (ALLR) rating was a downgraded with a price target of $0.00 to $0.00. The current price Allarity Therapeutics (ALLR) is trading at is $1.52, which is out of the analyst's predicted range.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment